sur Nanohale AG (ETR:FYB)
Formycon AG and OneSource Specialty Pharma Forge Biosimilars Manufacturing Partnership
Formycon AG and OneSource Specialty Pharma Limited have announced a strategic manufacturing partnership aimed at biosimilars. OneSource will act as the strategic manufacturing partner for Formycon, providing integrated Drug Substance and Drug Product manufacturing from its Bangalore-based biologics facility. This collaboration combines Formycon's development expertise with OneSource's manufacturing capabilities to ensure reliable production and supply of biosimilars for global markets.
Dr. Stefan Glombitza, CEO of Formycon, highlighted the importance of scalable and cost-efficient manufacturing in their FYB4Growth strategy. Neeraj Sharma, CEO of OneSource, expressed enthusiasm for the partnership, emphasizing India's potential as a global hub for biologics. The partnership aims to enhance global access to biosimilars by ensuring high-quality and scalable manufacturing. This collaboration reflects a mutual commitment to expanding access to biologics and reinforces India's position in the pharmaceutical manufacturing landscape.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Nanohale AG